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Abstract
Chronic Granulomatous Disease (CGD), a disorder of the NADPH oxidase system, results in phagocyte functional
defects and subsequent infections with bacterial and fungal pathogens (such as Aspergillus species and Candida
albicans). Deletions and missense, frameshift, or nonsense mutations in the gp91
phox gene (also termed CYBB),
located in the Xp21.1 region of the X chromosome, are associated with the most common form of CGD. When
larger X-chromosomal deletions occur, including the XK gene deletion, a so-called “Contiguous Gene Deletion
Syndrome” may result. The contiguous gene deletion syndrome is known to associate the Kell phenotype/McLeod
syndrome with diseases such as X-linked chronic granulomatous disease, Duchenne muscular dystrophy, and X-
linked retinitis pigmentosa. These patients are often complicated and management requires special attention to
the various facets of the syndrome.
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Introduction
Primary immune deficiencies can involve defects in pha-
gocyte function, resulting in Chronic granulomatous dis-
ease (CGD) [1,2]. CGD is characterized by repeated
infections with bacterial and fungal pathogens, as well as
the formation of granulomas [1-4]. In this disease, the
NADPH oxidase system is dysfunctional due to specific
gene mutations, culminating in an inability of the pha-
gocyte to eliminate pathogenic organisms. Typically, this
defect in phagocyte function leads to serious infections
including Staphylococcus aureus, Pseudomonas species,
Nocardia species, fungi such as Aspergillus species, and
Candida albicans. Significant morbidity and mortality
may result.
The genetic defect in CGD can be transmitted in
either an X-linked or autosomal recessive manner
[1,5-7]. Genes regulating NADPH assembly and function
are most commonly affected. When X-linked disease
occurs, deletion of the contiguous genes that border the
gene on the X chromosome that regulates NADPH
function can result in the “contiguous X-chromosome
gene deletion syndrome” [8-12]. Mutations extending
into these surrounding genes may result in Duchenne
muscular dystrophy (DMD) or Retinitis pigmentosa
[13,14]. Other conditions, such as the McLeod syn-
drome, may also result in such patients [15-18]. In some
selected situations, mutations in other innate immune
system genes such as the complement pathway genes
(especially mannose binding lectin) may further compli-
cate disease severity and management [19].
CGD and the Contiguous Gene Deletion Syndrome
X-linked CGD is responsible for the majority (> 60%) of
the CGD cases seen in the United States [2,20]. The X-
linked type is caused by a mutation in the gp91
phox
gene, which is also referred to as the cytochrome b-245
beta polypeptide (CYBB) gene. Autosomal recessive
CGD is seen in the remaining 35% of cases and arises
due to mutations of the other components of the
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include p22
phox ,p 6 7
phox,a n dp 4 7
phox . Of these, the
dominant mutation observed is in the p22
phox gene
which accounts for almost 25% of the autosomal reces-
sive cases. The associated phenotypes are also referred
to as the A22/A47/A67 CGD. The phenotype of the
gp91
phox gene mutation is referred to as X-CGD. Muta-
tions of other nearby genes, p40
phox and Rac, have yet
to be associated with any CGD phenotype [2,20]. Gene
location and associated disease state are described in
Table 1.
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region of the X chromosome (Figure 1A). Deletions and
frameshift, missense, nonsense, or splice site mutations
of the CYBB gene can contribute to defects seen in
CGD. On occasion, larger X-chromosomal deletions
may occur. The Kell locus or XK gene, which encodes
an essential glycoprotein for Kell antigen expression,
may be involved in such cases. These larger deletions
that extend across multiple genes will result in manifes-
tations of the “Contiguous gene deletion syndrome”
(Figure 1B)[8,9]. As stated earlier, this syndrome (Figure
2) encompasses the McLeod syndrome in association
with X-linked Chronic granulomatous disease, Duch-
enne muscular dystrophy, and/or X-linked Retinitis pig-
mentosa [10,14,15].
The Kell blood group and Kell antigens
The Kell blood group system was first identified by
Coombs in 1946 when ABO and Rhesus incompatibility
were excluded in a mother, Mrs. Kelleher, who had
delivered a baby with hemolytic anemia. It is now con-
sidered the third most important blood group system
based on immunological potency. The antigens of the
Kell system are numerous and complex [17,21-25]. The
K antigen may be the most significant antigen of the
Kell system with regards to development of disease and
transfusion-related complications.
The Kell antigens, which are encoded for by the KEL
gene, are carried by the transmembrane Kell glycopro-
tein (XK) (Figure 3). The KEL gene is found on chromo-
some 7 (7q33). It is highly polymorphic [26,27] and
encodes the numerous Kell antigens. There appear to be
two major co-dominant alleles referred to as k (Cellano)
and K (Kell) that differ by a single amino acid change;
the latter is considered the more potent immunogen.
Although there have been 25 Kell antigens identified,
the “k” antigen is the most common. The phenotype K-
k+ is seen in a majority of Caucasians and African
Americans, while a smaller number (9%) of Caucasians
may be K+k+. When the Kell antigens are absent on red
blood cells, this is referred to as the rare K null pheno-
type (K0). Individuals with this phenotype produce anti-
Ku antibodies that target RBCs expressing Kell antigens,
but are otherwise healthy. Anti-Ku antibodies may result
in the development of moderate to severe transfusion
reactions following transfusion from a donor who is Kell
+. For this reason, patients with the K0 phenotype
should only be transfused with K0 blood products. Anti-
Ku antibodies are also involved in fetomaternal immuni-
zation. Pregnant females with the K0 phenotype produce
anti-Ku antibodies which target Kell antigens located on
the surface of fetal RBCs. These antibodies are responsi-
ble for the third most common cause of hemolytic ane-
mia in the newborn. The McLeod phenotype is seen
with a severe reduction in Kell antigens; this can be
associated with CGD [23-25].
The McLeod Syndrome
The McLeod syndrome is characterized by an absence
of the Kx antigen on red blood cells. This is associated
with weak expression of Kell antigens. Kell antigens
are covalently bound to the RBC transmembrane XK
protein. When XK is absent on RBC membranes,
McLeod syndrome develops. In this syndrome, the Kell
antigens are weakly expressed which leads to the
appearance of abnormally shaped RBCs (referred to as
acanthocytes) [28]. Characteristics of the Kell and XK
p r o t e i n sa r es h o w ni nT a b l e2 .T h eM c L e o ds y n d r o m e
manifests either as a hemolytic anemia following trans-
fusion of Kell(+) RBC to a Kell(-) recipient or as a
delayed onset (usually in the 4
th decade or later) of
neuropsychological or cardiovascular impairment in
patients with CGD.
Table 1 Gene and Chromosomal localization
Condition Gene Chromosome Comments Clinical
X-linked CGD CYBB XP21 Deletion or missense, nonsense and/or frameshift mutations may
occur
Opportunistic infection
Autoimmunity
Organ dysfunction
McLeod
syndrome
XK XP21 Absent Kx antigen and weak expression of Kell on RBC surface
XK is linked to Kell blood group antigen
Kell locus mutations can also lead to the syndrome
Acanthocytosis
Elevated CPK
Huntington’s chorea-like disease
Muscle weakness and atrophy
Cardiomyopathy
Psychiatric disease Cognitive
impairment
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Page 2 of 6Figure 1 X Ka n dC Y B Ba r en e i g h b o r i n gg e n e s . A. Idiogram of human chromosome X at 550 banding resolution. The bar indicates the
location XK and CYBB genes and is expanded below to show the genomic region. B. Genomic context of Xp21.1. The region of chromosome X
from 37,500 to 37,700 K is shown. Arrows indicate the location of the XK and CYBB genes. Numbering is based upon GenBank accession
number NC_000023.10.
Figure 2 Complicating conditions often seen in the Contiguous gene deletion syndrome associated with chronic granulomatous
disease.
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covered accidentally by routine screening of apparently
healthy blood donors [29]. Affected individuals may be
detected by elevated creatinine kinase levels and
acanthocytosis [29]. In addition to extravascular hemoly-
tic anemia, patients manifesting the McLeod syndrome
may develop multisystem disease, including splenome-
galy and neurological problems late in life [30]. With
time, neurological complications and manifestations of
Huntington’s disease-like disorder may become evident.
The neurological symptoms may appear between the 2
nd
and 6
th decades of life. Besides Huntington’s chorea-like
disease and cardiomyopathy, patients develop muscle
weakness and atrophy, psychiatric disease, and cognitive
impairment [16,17,29-34]. In some cases, the disorder
that develops may be indistinguishable from neuroa-
canthocytosis with chorea, orofacial dyskinesia, dysar-
thria, and dementia [35]. It is therefore essential to
evaluate these more complex patients for the conditions
listed in Table 3 including generalized seizures and
Figure 3 Structure of the XK and Kell proteins.
Table 2 Characteristics of the Kell system
Kell
protein
93 kDa type II membrane glycoprotein
Short N-terminal intracellular segment with one cysteine
residue
Single transmembrane section
Large extracellular domain (665 amino acids with 15
cysteine residues)
One cysteine residue (Cys72) in extracellular domain binds
XK protein
Homology to certain zinc endoproteases
Demonstrates endothelin-3 converting enzymatic activity
Encoded by the KEL gene (7q33)
K0 (null) RBC lack Kell antigens but have enhance XK
activity
KEL gene is inherited autosomally
XK
protein
Molecular weight of 50.9 kDa
10 transmembrane segments
Short N-terminal domain (intracellular)
Large C-terminal domain (intracellular)
A large hydrophilic loop (Figure 3)
Single cysteine residue that binds covalently to Cys72 on
Kell
Loss of XK leads to McLeod syndrome that has X-linked
inheritance
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atrial arrhythmia.
Duchenne Muscular Dystrophy
DMD is an X-linked progressive myopathy that can occa-
sionally complicate a contiguous gene deletion syndrome
involving X-linked CGD [13,34]. In the case reported by
Kang et al., the DMD manifestations developed several
years after the successful treatment of CGD by allogeneic
stem cell transplantation [13]. This male child had a
large scale deletion spanning the region between CYBB
and DMD on the X chromosome. No dystrophin was
expressed in the muscle, and a muscle biopsy demon-
strated the typical histological changes of DMD. Dystro-
phin is located on the short arm of the X chromosome at
the locus p21. Deletion of the dystrophin gene is com-
monly seen in DMD-especially when complicating CGD
and the contiguous gene deletion syndrome. In other
cases, point mutations and/or microdeletions may occur.
Western blotting or immunocytochemistry for dystro-
phin protein expression can also be used diagnostically.
The disease manifests as clumsy gait, development of the
typical “Gower’s maneuver” (the child has to place one
h a n do nt h ek n e ei no r d e rt os t a n du p r i g h tw h i l er i s i n g
from a seated position) and calf muscle changes (charac-
terized by pseudo-hypertrophy). The child develops pro-
gressive muscular weakness that results in frequent falls,
inability to climb and, eventually, culminates in the child
becoming wheelchair bound. Cardiomyopathy and
respiratory failure may result in severe morbidity and
mortality. Treatment may involve physiotherapy, applica-
tion of a brace, and surgery where indicated. Attempts
are being made to develop pharmacological approaches
(such as the use of glucocorticoids, not without adverse
effects, or more muscle-specific therapies) and gene ther-
apy to reverse the disease process.
Retinitis Pigmentosa
This is a condition that leads to progressive visual loss
due to loss of the photoreceptors. There are several
reports of Retinitis pigmentosa complicating CGD and
the Contiguous gene deletion syndrome [14,34,36-38].
Ophthalmic examination reveals fairly typical findings
including pigment loss, waxy pallor of the optic nerve
head, and attenuation of the retinal arterioles. There are
several genetic variants of Retinitis pigmentosa. The X-
linked type, involving mutations of the RPGR gene, is
seen in the Contiguous gene deletion syndrome. Clini-
cally, there is progressive loss of visual acuity and night
blindness followed by a rapid decline in vision and
blindness by the 4
th decade.
Conclusion
CGD is a chronic disease caused by a mutation in a
gene encoding essential components of NADPH oxidase
function. As a result, increased susceptibility for infec-
tions occurs. The more common form of CGD involves
the gene regulating NADPH function that is located on
the X-chromosome. A deletion that results in X-linked
CGD can also involve contiguous genes. This results in
the “contiguous X-chromosome gene deletion syn-
drome” with manifestations of the McLeod syndrome,
Duchenne muscular dystrophy and X-linked retinitis
pigmentosa that further complicate disease severity and
management.
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Table 3 Contiguous Gene Syndrome (including McLeod
Syndrome) complicating CGD
Clinical component Evaluation (selected)
Myopathy CPK level (serum)
EMG/NCS
Hemolytic Anemia Reticulocyte cell count
Low haptoglobin
Acanthocytosis
Late-onset neurological syndrome
Cerebral atrophy CT/MRI
Neuropathy EMG/NCS
Huntington’s chorea-like disease CT/MRI
Neuropsychological and cognitive
impairment
Neuropsychological
testing
Myopathy/DMD EMG/NCS
Muscle biopsy*
Seizures EEG
Glomerulopathy with renal failure Serum creatinine level
24 hour urine analysis
Renal imaging
+/- kidney biopsy
Cardiovascular disease
Cardiomyopathy ECHO
Arrythmia EPS
CPK = creatine phosphokinase; EMG/NCS = electromyography and nerve
conduction study
CT = computed tomography; MRI = magnetic resonance imaging; EEG =
electroencephalography
ECHO = echocardiography (transthoracic or transesophageal); EPS =
electrophysiological studies
DMD = Duchenne muscular dystrophy; * = typical muscle histology of DMD
and absent muscle dystrophin
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